Ganjian Shahrouz, Ourian Ariel J, Shamtoub Gabreal, Wu Jashin J, Murase Jenny E
Department of Dermatology, University of California, Irvine, Irvine, California, USA.
Dermatol Online J. 2009 May 15;15(5):4.
Due to the ability of imiquimod (Aldara, 3M Pharmaceuticals) to rapidly and potently stimulate both innate and adaptive arms of the immune system, imiquimod has rapidly been recognized as a potential candidate for off-label use in over 60 conditions as presented in numerous case reports, letters, and small trials. It is our goal to examine and consolidate this impressive body of literature in order to provide the practicing dermatologist with a quick reference of the conditions that have been successfully treated with imiquimod, the dosages used, and the success rates of treatments.
由于咪喹莫特（艾达乐，3M制药公司）能够快速且有效地刺激免疫系统的先天性和适应性分支，在众多病例报告、信函及小型试验中表明，咪喹莫特已迅速被视为60多种病症的潜在非标签用药候选药物。我们的目标是审视并整合这一数量可观的文献，以便为皮肤科执业医生提供一份快速参考资料，内容涵盖已成功用咪喹莫特治疗的病症、所用剂量及治疗成功率。
